Table 1.
Patient demographics and baseline characteristics in AFM11-101
| Safety population (n = 16) |
|
|---|---|
| Age (y), mean (SD) | 56.5 (16.52) |
| Male, n (%) | 10 (62.5) |
| Diagnosis NHL, n (%) | 16 (100) |
| Time since diagnosis (y), mean (SD) | 4.80 (4.35) |
| Disease status at screening, n (%) | |
| Stage I | 1 (6.3) |
| Stage II | 1 (6.3) |
| Stage III | 2 (12.5) |
| Stage IV | 12 (75) |
| Previous treatments, n (%) | |
| At least 1 line of prior systemic therapy | 16 (100) |
| Chemotherapy alone | 15 (93.8) |
| Othera | 9 (56.3) |
| ASCT | 7 (43.8) |
| Anti-CD20 therapy | 6 (37.5) |
| Targeted small molecule kinase | 4 (25.0) |
| Immunotherapyb | 3 (18.8) |
| ≥ 1 prior radiotherapy | 5 (31.3) |
ASCT Autologous stem cell transplant, NHL Non-Hodgkin’s lymphoma, SD Standard deviation
aOther lines include R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
bImmunotherapy included blinatumomab, rituximab-bendamustine, rituximab-bendamustine or rituximab-pinxantrone